OncologyAI Registry
Public, curated registry of AI diagnostics in oncology
← Back to registry

Afirma Genomic Sequencing Classifier

Veracyte
Genomic + AI thyroid

RNA-sequencing and AI classification of indeterminate thyroid nodules to reduce unnecessary surgery.

Regulatory statusLDT
LDTYes
NY CLEPcleared
CLIA-certified labYes

Laboratory-developed test (LDT) offered under CLIA. Not reviewed or cleared by the FDA. Validation is the responsibility of the offering CLIA-certified laboratory.

Study designProspective
Cohort size183 patients; 191 samples — Prospective, multicenter, blinded cohort: 183 patients with cytologically indeterminate (Bethesda III/IV) thyroid nodules across 49 academic and community centers; 191 FNA samples had adequate residual RNA for analysis; ground truth = blinded expert histopathology.
Number of validation sites49
Site geographyMulti-center (US)
ComparatorGold-standard test
Primary endpointSensitivity / specificity
Primary resultSensitivity 91% (95% CI 79–98%); Specificity 68% (95% CI 60–76%); NPV 96% (95% CI 90–99%) at a 24% cancer prevalence in the Bethesda III/IV cohort; PPV 47% (95% CI 36–58%).
External validationYes — Prospective multicenter cohort recruited independently of Afirma GSC training data; blinded histopathology adjudication. · Performance validated against blinded expert histopathology.
Peer-reviewedYes
FDA decision summary

Key publications

Limitations noted

Patel 2018 cohort is small (N=191); cancer prevalence (24%) is higher than some real-world indeterminate-nodule populations, which affects NPV. Test is intended as a rule-out (high NPV) — PPV is moderate; benign Afirma calls should still be followed by ultrasound surveillance per ATA guidelines. Afirma GSC is LDT — no FDA analytical review.

AvailableYes
How to cite this entry
Elbakri A. OncologyAI Registry: Afirma Genomic Sequencing Classifier. Available at: https://oncologyairegistry.org/tools/veracyte-afirma-gsc.html. Accessed [date].